Chenglong Zhao

Chenglong Zhao

Auto-generated profile, based on publicly available information

Chenglong Zhao

Second Military Medical University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2018 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
CZChenglong Zhao
Chenglong Zhao
YLYan Lou
Yan Lou
YWYao Wang
Yao Wang
DWDongsheng Wang
Dongsheng Wang
LTLiang Tang
Liang Tang
JXJianru Xiao
Jianru Xiao
Breast cancer is prone to form bone metastases and subsequent skeletal‐related events (SREs) dramatically decrease patients’ quality of life and survival. Prediction and early management of bone lesions are valuable; however, proper prognostic models are inadequate. In the current study, we reviewed a total of 572 breast cancer patients in three microarray data sets including 191 bone metastases and 381 metastases‐free. Gene set enrichment analysis (GSEA) indicated less aggressive and low‐grade features of patients with bone metastases compared with metastases‐free ones, while luminal subtypes are more prone to form bone metastases. Five bone metastases‐related genes (KRT23, REEP1, SPIB, ALDH3B2, and GLDC) were identified and subjected to construct a gene expression signature‐based nomogram (GESBN) model. The model performed well in both training and testing sets for evaluation of breast cancer bone metastases (BCBM). Clinically, the model may help in prediction of early bone metastases, prevention and management of SREs, and even help to prolong survivals for patients with BCBM. The five‐gene GESBN model showed some implications as molecular diagnostic markers and therapeutic targets. Furthermore, our study also provided a way for analysis of tumor organ‐specific metastases. To the best of our knowledge, this is the first published model focused on tumor organ‐specific metastases.

18 January 2018 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
XGXin Gao
Xin Gao
CZChenglong Zhao
Chenglong Zhao
SHShaohui He
Shaohui He
TFTianqi Fan
Tianqi Fan
WXWei Xu
Wei Xu
JXJianru Xiao
Jianru Xiao

3 January 2019 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
ZZZhichao Zhang
Zhichao Zhang
HGhaiyi gong
haiyi gong
CZChenglong Zhao
Chenglong Zhao
DWDongsheng Wang
Dongsheng Wang
MQMing Qian
Ming Qian
JXJianru Xiao
Jianru Xiao

1 July 2026 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CYCheng Yang
Cheng Yang
QJQi Jia
Qi Jia
CZChenglong Zhao
Chenglong Zhao
XYXinghai Yang
Xinghai Yang
HWHaifeng Wei
Haifeng Wei
JXJianru Xiao
Jianru Xiao
PURPOSE: Limited efficacy of current treatments for chordoma calls for novel therapeutic options. Combination of immune checkpoint inhibitors and antiangiogenic drugs has altered the landscape of cancer treatment but has rarely been investigated in chordoma. METHODS: An investigator-initiated, single-center, phase II trial was conducted on camrelizumab (a PD-1 inhibitor, 200 mg once every 2 weeks) plus apatinib (an antiangiogenic drug, 250 mg and 500 mg on alternate days, that is, 250 mg one day, 500 mg the next day, alternating) in patients with refractory chordoma for 4-week cycles. The primary end point was the objective response rate (ORR) per RECIST version 1.1. Secondary end points included ORR per Choi criteria, progression-free survival (PFS), overall survival, the disease control rate, median duration of response (mDoR), safety, and quality of life. The trial is registered with Chictr.org.cn (ChiCTR2100042938). RESULTS: Of the 38 patients initially screened between September 2021 and October 2024, 33 were enrolled. Median follow-up duration was 20.8 months (IQR, 13.35-26.55). ORR was 24.2% (8/33 [95% CI, 11.1 to 42.3]) per RECIST 1.1 and 48.5% (16/33 [95% CI, 30.8 to 66.5]) per Choi criteria. The median PFS was 28.4 months (95% CI, 13.53 to 43.28). The mDoR was not reached per RECIST 1.1 and was 22.2 months (95% CI, 12.5 to not reached) per Choi criteria. CDKN2A copy-number deletion or homozygous deletion was found to associate with worse prognosis. The most common grade 3 or 4 treatment-related adverse events included increased aspartate aminotransferase (13 [39.4%]) and increased alanine aminotransferase (11 [33.3%]). No treatment-related deaths occurred. CONCLUSION: Combination of camrelizumab and apatinib offered encouraging efficacy with manageable toxicity in chordoma treatment. CDKN2A alterations are associated with worse prognosis and may prove to be a potential biomarker for treatment selection.